Compare companies
Put any US companies we track side by side — SEC-sourced financials, ratios, forensic scores, and our Quality Score. Add up to four. No market price, no paywall.
SUPERNUS PHARMACEUTICALS, INC.
| Metric | SUPERNUS PHARMACEUTICALS, INC. Other |
|---|---|
| Quality Score | 57 / 100 |
| Revenue (latest) | $719M |
| Net income (latest) | −$39M |
| Operating margin | −8.7% |
| Net margin | −5.4% |
| Return on equity | −3.6% |
| Return on assets | −2.7% |
| Return on capital (ROCE) | −5.6% |
| Debt / equity | 0.37× |
| Revenue growth (YoY) | 8.6% |
| Altman Z″ (distress) | 5.11 |
| Accruals / assets | −5.9% |
Latest reported figures from each company's own SEC filings (XBRL) plus our derived scores. Blank where a line item isn't cleanly tagged — never estimated. Descriptive factors, not advice. Open a company for its full multi-year history.